AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

IBESARTAN

12 registrations across 2 African markets— 12 active

Markets with IBESARTAN

Recent registrations

Brand / ProductMarketHolderStatusExpires
APROVEL TABLETS (Each tablet contains Ibesartan 150mg)🇬🇭GhanaactiveSept 2029
APROVEL TABLETS (Each tablet contains Ibesartan 150mg)🇬🇭GhanaactiveSept 2029
APROVEL TABLETS (Each tablet contains Ibesartan 300mg)🇬🇭GhanaactiveSept 2027
APROVEL TABLETS (Each tablet contains Ibesartan 300mg)🇬🇭GhanaactiveSept 2027
APROVEL TABLETS (Each tablet contains Ibesartan 150mg)🇬🇭GhanaactiveSept 2027
APROVEL TABLETS (Each tablet contains Ibesartan 150mg)🇬🇭GhanaactiveSept 2027
Vepran
comprimé pelliculé / 300 mg
🇸🇳Senegalactive
IRBESARTAN GRB
comprimé pelliculé / 75 mg
🇸🇳SenegalBIOGARANactive
Vepran
comprimé pelliculé / 150 mg
🇸🇳Senegalactive
IRBESARTAN GRB
comprimé pelliculé / 75 mg
🇸🇳SenegalBIOGARANactive
Vepran
comprimé pelliculé / 300 mg
🇸🇳Senegalactive
Vepran
comprimé pelliculé / 150 mg
🇸🇳Senegalactive

IBESARTAN in Africa — Regulatory Overview

IBESARTAN is registered across 2 African markets with 12 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Senegal. AfricaRegulatory refreshes this data daily from official government sources.

Of the 12 registrations, 12 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.